CXCL9 and triple-negative breast carcinoma: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9&lt;sup&gt;+&lt;/sup&gt; monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer.